Clinical Trial

Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia

Study acronym: CarChem
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational study of the occurrence of cardiac toxicity in patients with breast cancer,lymphoma or leukemia receiving chemotherapy including an anthracycline. Patients will be identified at the oncology clinic and will be included in the study if all eligible criteria are met. The study will involve retrospective and prospective evaluations. Safety will be assessed through reporting of serious adverse events (SAEs) related to study procedures.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2020-09-01; most recent amendment 2025-06-11.
Status change: Recruiting → Active, Not Recruiting 2025-06-11
Status change: Not Yet Recruiting → Recruiting 2021-12-15
Trial Details
NCT Number NCT04541212
Lead Sponsor Montreal Heart Institute
Collaborators: AstraZeneca
Conditions Breast Cancer, Lymphoma, Leukemia
Enrollment 169 participants
Start Date 2021-12-02
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-15